Fig. 1From: A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopeniaTrial profile. HETROM-2.5, the dose was titrated from an initial dosage of once-daily 2.5Â mg hetrombopag; HETROM-5, the dose was titrated from an initial dosage of once-daily 5Â mg hetrombopag; AEs, adverse events. *Eligible patients were randomly allocated at a ratio of 4:4:1:1 to the HETROM-2.5 group, the HETROM-5 group, and matching placebo groups. The two matching placebo groups were pooled as the Placebo groupBack to article page